The "Retinal Vein Occlusion Treatment Market by Treatment Type (Anti-VEGF Injection, Corticosteroid Treatment, Laser Therapy), Age Group (40-60, Above 60, Below 40), Condition Type, End User - Global ...

New data presented at the American Society of Retina Specialists 2024 examine the benefits and adverse event profiles of two ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they ...

AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris ...

The researchers found a significant decrease in the peripapillary retinal nerve fiber layer (pRNFL), macular RNFL, ganglion cell inner plexiform layer (GCIP), and total macular volume thickness or ...

The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...

also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 ...

Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...

Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing novel treatments for degenerative retinal diseases ... in advanced dry age-related macular degeneration (AMD).

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...